YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels

Zaiwen FanDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Bo LiuDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China, ;Graduate Student Ministry of Education, Hebei North University, Zhangjiakou, China,

Shuai ZhangDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China, ;Graduate Student Ministry of Education, Hebei North University, Zhangjiakou, China,

Huiguo LiuDepartment of Respiratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, and

Yang LiInstitute of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China

Dong WangDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Ying LiuDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Jian LiDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Ning WangDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Yi LiuDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China,

Bo ZhangDepartment of Respiratory Medicine, General Hospital of PLA Air Force, Beijing, China, Correspondence[email protected]

show all

Abstract

To test the hypothesis that chronic hypoxic pulmonary hypertension (CH-PH) is associated with increased survivin and decreased voltage-gated potassium (K_V) channels expression in pulmonary arteries, rats were randomized as: normoxia (N); normoxia + YM155, survivin suppressor (NY); hypoxia (H); hypoxia + YM155 (HY). HY group had significantly reduced pulmonary arterial pressure, right ventricular weight and right ventricular hypertrophy compared with H group. Survivin mRNA and protein were detected in pulmonary arteries of rats with CH-PH, but not rats without CH-PH. YM155 downregulated survivin protein and mRNA. K_V channel expression and activity were upregulated after YM155 treatment. Survivin may play a role in the pathogenesis of CH-PH.

Keywords

Declaration of interest

Authors have no conflicts of interest to declare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels

Information for

Open access

Opportunities

Help and information

YM155, a selective survivin inhibitor, reverses chronic hypoxic pulmonary hypertension in rats via upregulating voltage-gated potassium channels

Abstract

Declaration of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature